The FDA approved an oral formulation of Novo Nordisk’s weight‑loss drug Wegovy, marking the first pill version of a GLP‑1 therapy cleared for obesity. Regulators cleared the pill for weight management and for reducing cardiovascular risk, extending the label of the injectable semaglutide formulation. Novo Nordisk will pivot commercialization and access plans toward oral distribution to reach patients who avoid injections. Clinicians and payers will watch rollout dynamics closely: the oral route removes a major access friction but raises questions on coverage, copays and demand. The FDA decision follows large outcomes and obesity trials that established the drug’s efficacy and cardiovascular signal. GLP‑1s are glucagon‑like peptide‑1 receptor agonists, a class that reduces appetite and improves glycemic control; the pill could materially enlarge the market for obesity therapeutics.